NasdaqGS:ALNYBiotechs
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors
Earlier in May 2026, Alnylam Pharmaceuticals reported new HELIOS-B Phase 3 analyses showing vutrisiran delivered durable transthyretin knockdown, consistent clinical benefits across high-risk ATTR-CM subgroups, and low, placebo-like vitamin A-related ocular event rates over more than 25,000 patient-years of exposure.
The company also launched the large DemonsTTRate real-world outcomes study and highlighted over 13,000 patient-years of global vutrisiran experience, deepening the clinical...